Ohmi Masashi, Shishido Yuji, Inoue Tadashi, Ando Kazuo, Fujiuchi Akiyoshi, Yamada Akiko, Watanabe Shuzo, Kawamura Kiyoshi
Research and Development, RaQualia Pharma Inc., 5-2 Taketoyo, Aichi 470-2341, Japan.
Research and Development, RaQualia Pharma Inc., 5-2 Taketoyo, Aichi 470-2341, Japan.
Bioorg Med Chem Lett. 2014 Dec 1;24(23):5364-8. doi: 10.1016/j.bmcl.2014.10.074. Epub 2014 Oct 29.
A novel series of 2-pyridyl-benzensulfonamide derivatives have been identified as selective and orally active TRPM8 antagonists via high throughput screening (HTS). Exploration of the structure-activity relationships of compound 1 has led to the identification of RQ-00203078 (compound 36) as a highly selective, potent and orally available TRPM8 antagonist. RQ-00203078 demonstrated excellent in vivo activity in a dose dependent manner with an ED50 value of 0.65 mg/kg in the icilin-induced wet-dog shakes model in rats after oral administration and may become an important pharmacological tool for fully assessing the potential therapeutic use of the targets activated by cold stimulation.
通过高通量筛选(HTS),已鉴定出一系列新型的2-吡啶基苯磺酰胺衍生物为选择性且口服活性的TRPM8拮抗剂。对化合物1构效关系的探索导致确定RQ-00203078(化合物36)为一种高选择性、强效且口服可用的TRPM8拮抗剂。RQ-00203078在大鼠的艾西利定诱导湿狗抖模型中口服给药后,以剂量依赖性方式表现出优异的体内活性,ED50值为0.65 mg/kg,并且可能成为全面评估冷刺激激活靶点潜在治疗用途的重要药理学工具。